The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis
Main finding · VTE by IgG anti-CCP2 statusResult — go to the resultHazard ratio 1.33 95% CI 1.00–1.78Authors' conclusion
Anti-CCP2, load of ACPA fine-specificities and IgM RF at RA diagnosis are associated with an increased risk of future VTE in RA. Antibodies to citrullinated fibrinogen did not differ substantially from other ACPA fine-specificities. Autoreactivity to other post-translational modifications was not associated with VTE risk.
Study context
- Population
- Patients with newly diagnosed RA; sera from RA diagnosis centrally analysed for anti-CCP2, 20 anti-citrullinated protein antibody (ACPA) fine-specificities, anti-carbamylated and anti-acetylated antibodies and RF by isotypemedian 16 years follow-up
- Participants
- 2,814 patients
- Exposure
- Autoantibody-positive vs autoantibody-negative at RA diagnosis
- Outcome
- Incident first-ever VTE
Methodological detailsCox regression adjusted for age, sex and calendar period of RA diagnosis, register linkages
- Cox regression adjusted for age, sex and calendar period of RA diagnosis
- Register linkages
Main finding
VTE by IgG anti-CCP2 status
Hazard ratio
1.33
95% CI 1.00–1.78
IgG anti-CCP2 positivevs IgG anti-CCP2 negative
HR 1.33 (95% CI 1.00–1.78)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| VTE by IgM RF statusIgM RF positivevs IgM RF negative | 1.38 (1.04–1.82) | |
| 0.512Hazard ratio (log scale) |
- Venous thromboembolic (VTE) by IgM RF status: independent from smoking and HLA-DRB1 shared epitope alleles
VTE by IgM RF status
- No other RF isotypes associated with VTE
VTE by carbamylated or acetylated antibody reactivities
- None of the carbamylated or acetylated antibody reactivities associated with VTE
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis. Rheumatology (Oxford). Published 18 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →